Advertisement

Clinical and Experimental Nephrology

, Volume 13, Issue 5, pp 430–437 | Cite as

Lipoprotein glomerulopathy induced by ApoE-Sendai is different from glomerular lesions in aged apoE-deficient mice

  • Atsunori Ishimura
  • Maho Watanabe
  • Hitoshi Nakashima
  • Kenji Ito
  • Katsuhisa Miyake
  • Shizue Mochizuki
  • Yasushi Ishigaki
  • Takao Saito
Original Article

Abstract

Objective

A mutant of apolipoproteinE (apoE), ApoE-Sendai (Arg145Pro), is one of the major causative factors of human lipoprotein glomerulopathy (LPG). An apoE-deficient mouse with introduced ApoE-Sendai gene (ApoE-Sendai mouse) developed a murine counterpart of LPG, whereas it was also reported that apoE-deficient mouse (apoE KO mouse) spontaneously developed LPG-like lesion regardless of introduction of ApoE-Sendai gene. In the present study, we differentiated renal lesions between these two models by detailed analyses of histology and lipoprotein profile, and clarified the role of apoE variants.

Method

ApoE-Sendai mice were induced by injection of adenovirus vectors. The kidneys showing LPG-like lesions in apoE-Sendai and apoE KO mice were histopathologically evaluated. Plasma lipids and lipoproteins of both mice were also examined.

Results

Histological alteration of the kidney in ApoE-Sendai mice was observed with light microscopy (in 40 out of 50 mice; mild 24, moderate 13, severe 3). Characteristic lesions were dilated vascular lumens mimicking lipoprotein thrombi in human LPG. Similar changes were found in hematoxylin–eosin stained sections of aged apoE KO mice. Meanwhile, periodic acid–Schiff, Azan Mallory, and Oil red O/Sudan III stained sections revealed that the dilated lumens of ApoE-Sendai mice mainly contained lipids and lipoproteins but those of aged apoE KO mice contained much other materials, e.g., proteins and fibrils. These findings were supported by electron micrographs, in which round-shaped droplets indicating lipoproteins were observed in ApoE-Sendai mice but not in aged apoE KO mice. In the kidney of apoE KO mice many anti-mouse CD68 Ab positive cells were detected. This contrasts with the result seen in ApoE-Sendai mice. The plasma lipoprotein compositions of the two types of mice were totally different.

Conclusion

It was certain that the kidneys of aged apoE KO mice showed morphological alteration, but the histological findings of glomerular lesions were different from those seen in the kidneys of ApoE-Sendai mice. According to the histological findings and plasma lipoprotein profile, ApoE-Sendai mice, not apoE KO mice, is a murine model for human LPG. This means that apoE variants are essential to LPG.

Keywords

Lipoprotein glomerulopathy ApoE-Sendai ApoE KO mice 

Notes

Acknowledgments

This study is supported in part by Grants-in-Aid (#16590806 and #18590917) from the Ministry of Education, Culture, Sports, Science, and Technology, and a grant for the Progressive Renal Disease Research Projects from the Ministry of Health, Labor, and Welfare, Japan.

References

  1. 1.
    Saito T, Sato H, Kudo K, Oikawa S, Shibata T, Hara Y, et al. Lipoprotein glomerulopathy: glomerular lipoprotein thrombi in a patient with hyperlipoproteinemia. Am J Kidney Dis. 1989;13:148–53.CrossRefPubMedGoogle Scholar
  2. 2.
    Saito T, Oikawa S, Sato H, Sasaki J. Lipoprotein glomerulopathy: renal lipidosis induced by novel apolipoprotein e variants. Nephron. 1999;83:193–201.CrossRefPubMedGoogle Scholar
  3. 3.
    Watanabe Y, Ozaki I, Yoshida F, Fukatsu A, Itoh Y, Matsuo S, et al. A case of nephrotic syndrome with glomerular lipoprotein deposition with capillary ballooning and mesangiolysis. Nephron. 1989;51:265–70.CrossRefPubMedGoogle Scholar
  4. 4.
    Oikawa S, Matsunaga A, Saito T, Sato H, Seki T, Hoshi K, et al. Apolipoprotein e sendai (arginine 145–proline): a new variant associated with lipoprotein glomerulopathy. J Am Soc Nephrol. 1997;8:820–3.PubMedGoogle Scholar
  5. 5.
    Konishi K, Saruta T, Kuramochi S, Oikawa S, Saito T, Han H, et al. Association of a novel 3-amino acid deletion mutation of apolipoprotein e (apo e tokyo) with lipoprotein glomerulopathy. Nephron. 1999;83:214–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Ando M, Sasaki J, Hua H, Matsunaga A, Uchida K, Jou K, et al. A novel 18-amino acid deletion in apolipoprotein e associated with lipoprotein glomerulopathy. Kidney Int. 1999;56:1317–23.CrossRefPubMedGoogle Scholar
  7. 7.
    Matsunaga A, Sasaki J, Komatsu T, Kanatsu K, Tsuji E, Moriyama K, et al. A novel apolipoprotein e mutation, e2 (arg25cys), in lipoprotein glomerulopathy. Kidney Int. 1999;56:421–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Ogawa T, Maruyama K, Hattori H, Arai H, Kondoh I, Egashira T, et al. A new variant of apolipoprotein e (apo e maebashi) in lipoprotein glomerulopathy. Pediatr Nephrol. 2000;14:149–51.CrossRefPubMedGoogle Scholar
  9. 9.
    Miyata T, Sugiyama S, Nangaku M, Suzuki D, Uragami K, Inagi R, et al. Apolipoprotein e2/e5 variants in lipoprotein glomerulopathy recurred in transplanted kidney. J Am Soc Nephrol. 1999;10:1590–5.PubMedGoogle Scholar
  10. 10.
    Saito T, Ishigaki Y, Oikawa S, Yamamoto TT. Role of apolipoprotein e variants in lipoprotein glomerulopathy and other renal lipidoses. Clin Exp Nephrol. 2001;5:201–8.CrossRefGoogle Scholar
  11. 11.
    Lalazar A, Weisgraber KH, Rall SC Jr, Giladi H, Innerarity TL, Levanon AZ, et al. Site-specific mutagenesis of human apolipoprotein e. Receptor binding activity of variants with single amino acid substitutions. J Biol Chem. 1988;263:3542–5.PubMedGoogle Scholar
  12. 12.
    de Knijff P, van den Maagdenberg AM, Frants RR, Havekes LM. Genetic heterogeneity of apolipoprotein e and its influence on plasma lipid and lipoprotein levels. Hum Mutat. 1994;4:178–94.CrossRefPubMedGoogle Scholar
  13. 13.
    Oikawa S, Suzuki N, Sakuma E, Saito T, Namai K, Kotake H, et al. Abnormal lipoprotein and apolipoprotein pattern in lipoprotein glomerulopathy. Am J Kidney Dis. 1991;18:553–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Saito T, Sato H, Oikawa S, Kudo K, Kurihara I, Nakayama K, et al. Lipoprotein glomerulopathy. Report of a normolipidemic case and review of the literature. Am J Nephrol. 1993;13:64–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Saito T, Sato H, Oikawa S. Lipoprotein glomerulopathy: a new aspect of lipid induced glomerular injury. Nephrology. 1995;1:17–24.CrossRefGoogle Scholar
  16. 16.
    Saito T. Abnormal lipid metabolism and renal disorders. Tohoku J Exp Med. 1997;181:321–37.CrossRefPubMedGoogle Scholar
  17. 17.
    Saito T, Ishigaki Y, Oikawa S, Yamamoto T. Etiological significance of novel apolipoprotein e variants in lipoprotein glomerulopathy. Trend Cardiovasc Med. 2002;12:67–70.CrossRefGoogle Scholar
  18. 18.
    Saito T, Oikawa S, Sato H, Sato T, Ito S, Sasaki J. Lipoprotein glomerulopathy: significance of lipoprotein and ultrastructural features. Kidney Int Suppl. 1999;71:S37–41.CrossRefPubMedGoogle Scholar
  19. 19.
    Mochizuki S, Moriya T, Naganuma H, Sasano H, Saito T. Significance of fat stains in serial sections from epon-embedded tissue samples for electron microscopy in renal diseases. Clin Exp Nephrol. 2001;5:240–5.CrossRefGoogle Scholar
  20. 20.
    Churg J, Berstein J, Glassock RJ, editors. Lipoprotein glomerulopahy. In: Renal disease: classification and atlas of glomerular disease, 2nd ed. New York-Tokyo: Igaku-Shoin; 1995. p. 450–1.Google Scholar
  21. 21.
    Finn LS, Berstein J. Lipoprotein glomerulopathy. In: Jennette JC, Olson JL, Schwartz MM, Silva FG, editors. Heptinstall’s pathology of the kidney. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 1203–5.Google Scholar
  22. 22.
    Appel GB, Radhakrishnan J, D’Agati V. Lipoprotein glomerulopathy. In: Brenner BM, editor. Brenner & Rector’s the kidney. 8th ed. Philadelphia: Saunders; 2008. p. 1118.Google Scholar
  23. 23.
    Fogo AB, Kashgarian M, editors. Lipoprotein glomerulopathy. In: Diagnostic atlas of renal pathology. 1st ed. Philadelpha: Elsevier Saunders; 2005. p. 168–71.Google Scholar
  24. 24.
    Ishigaki Y, Oikawa S, Suzuki T, Usui S, Magoori K, Kim DH, et al. Virus-mediated transduction of apolipoprotein e (apoe)-sendai develops lipoprotein glomerulopathy in apoe-deficient mice. J Biol Chem. 2000;275:31269–73.CrossRefPubMedGoogle Scholar
  25. 25.
    Wen M, Segerer S, Dantas M, Brown PA, Hudkins KL, Goodpaster T, et al. Renal injury in apolipoprotein e-deficient mice. Lab Invest. 2002;82:999–1006.CrossRefPubMedGoogle Scholar
  26. 26.
    Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein e. Science. 1992;258:468–71.CrossRefPubMedGoogle Scholar
  27. 27.
    Okazaki M, Usui S, Hosaki S. Analysis of plasma lipoproteins by gel permeation chromatography. In: Rifai N, Warmick GR, Dominiczak MH, editors. Handbook of lipoprotein testing. Washington, DC: AACC Press; 2000. p. 647–69.Google Scholar
  28. 28.
    Usui S, Nakamura M, Jitsukata K, Nara M, Hosaki S, Okazaki M. Assessment of between-instrument variations in a hplc method for serum lipoproteins and its traceability to reference methods for total cholesterol and hdl-cholesterol. Clin Chem. 2000;46:63–72.PubMedGoogle Scholar
  29. 29.
    Vlassara H, Bucala R, Striker L. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest. 1994;70:138–51.PubMedGoogle Scholar
  30. 30.
    Baylis C. Age-dependent glomerular damage in the rat. Dissociation between glomerular injury and both glomerular hypertension and hypertrophy. Male gender as a primary risk factor. J Clin Invest. 1994;94:1823–9.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Anderson S, Brenner BM. Effects of aging on the renal glomerulus. Am J Med. 1986;80:435–42.CrossRefPubMedGoogle Scholar
  32. 32.
    Zheng F, Cheng QL, Plati AR, Ye SQ, Berho M, Banerjee A, et al. The glomerulosclerosis of aging in females: contribution of the proinflammatory mesangial cell phenotype to macrophage infiltration. Am J Pathol. 2004;165:1789–98.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Diamond JR, Karnovsky MJ. Focal and segmental glomerulosclerosis: analogies to atherosclerosis. Kidney Int. 1988;33:917–24.CrossRefPubMedGoogle Scholar
  34. 34.
    Fazio S, Linton MF. Mouse models of hyperlipidemia and atherosclerosis. Front Biosci. 2001;6:D515–25.CrossRefPubMedGoogle Scholar
  35. 35.
    Liberopoulos E, Siamopoulos K, Elisaf M. Apolipoprotein e and renal disease. Am J Kidney Dis. 2004;43:223–33.CrossRefPubMedGoogle Scholar
  36. 36.
    Saito T, Matsunaga A, Oikawa S. Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases. Am J Kidney Dis. 2006;47:199–211.CrossRefPubMedGoogle Scholar

Copyright information

© Japanese Society of Nephrology 2009

Authors and Affiliations

  • Atsunori Ishimura
    • 1
  • Maho Watanabe
    • 1
  • Hitoshi Nakashima
    • 1
  • Kenji Ito
    • 1
  • Katsuhisa Miyake
    • 1
  • Shizue Mochizuki
    • 2
  • Yasushi Ishigaki
    • 3
  • Takao Saito
    • 1
  1. 1.Division of Nephrology and Rheumatology, Department of Internal Medicine, Faculty of MedicineFukuoka UniversityFukuokaJapan
  2. 2.Department of PathologyTohoku University HospitalSendaiJapan
  3. 3.Division of Molecular Metabolism and DiabetesTohoku University Graduate School of MedicineSendaiJapan

Personalised recommendations